CLINICAL TRIALS PROFILE FOR LATRODECTUS MACTANS
✉ Email this page to a colleague
All Clinical Trials for latrodectus mactans
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00657540 ↗ | Black Widow Spider Antivenin for Patients With Systemic Latrodectism | Completed | Rare Disease Therapeutics Inc. | Phase 3 | 2009-10-01 | The purpose of this study is to test the efficacy and safety of a new antivenom called Analatro® for treating black widow spider bites in patients who present to a hospital emergency room within 24 hours of symptom onset. This study will be a phase III, multi-center, double-blind, randomized controlled study that takes place in emergency departments. The primary aim of this study is to determine the proportion of patients in which pain control was not achieved by 48 hours post treatment. Secondary aims are as follows: 1) a reduction in pain intensity at the end of the treatment phase compared to baseline; 2) the proportion of patients with a clinically significant decrease in pain intensity at 30 minutes post-treatment; 3) the proportion of patients in which drug-related adverse events occurred; and 4) to determine if serious, drug-related adverse events in Analatro-treated patients occurred at a rate greater than one in 10 (10%). |
| NCT00657540 ↗ | Black Widow Spider Antivenin for Patients With Systemic Latrodectism | Completed | Instituto Bioclon S.A. de C.V. | Phase 3 | 2009-10-01 | The purpose of this study is to test the efficacy and safety of a new antivenom called Analatro® for treating black widow spider bites in patients who present to a hospital emergency room within 24 hours of symptom onset. This study will be a phase III, multi-center, double-blind, randomized controlled study that takes place in emergency departments. The primary aim of this study is to determine the proportion of patients in which pain control was not achieved by 48 hours post treatment. Secondary aims are as follows: 1) a reduction in pain intensity at the end of the treatment phase compared to baseline; 2) the proportion of patients with a clinically significant decrease in pain intensity at 30 minutes post-treatment; 3) the proportion of patients in which drug-related adverse events occurred; and 4) to determine if serious, drug-related adverse events in Analatro-treated patients occurred at a rate greater than one in 10 (10%). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for latrodectus mactans
Condition Name
Clinical Trial Locations for latrodectus mactans
Trials by Country
Clinical Trial Progress for latrodectus mactans
Clinical Trial Phase
Clinical Trial Sponsors for latrodectus mactans
Sponsor Name
